Eloralintide

unknown (auto-discovered: incretin-obesity, peptides-regenerative)

Also known as: LY3841136

Not graded

Classification

Peptide

Regulatory Status

investigational; registered trials: NCT07881458, NCT07881432 (PHASE3)

Unofficial source

Sources

Review

pending review

Overview

Unknown — Eloralintide was found by open discovery on 2026-10-26 and has not been researched yet.

Known

n/a

Unknown

Mechanism, dosing, safety, interactions and efficacy are unknown until research runs on this auto-discovered draft.

Study details: trial conditions, not guidance

These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.

Doses as found in each source, with its grade. What was found, not a direction.

Studies, trials and professional sources

n/a

Reddit, Facebook, Instagram, forums and blogs

n/a

Not gradedEloralintide is being studied in a registered trial: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes (NCT07881458; PHASE3; NOT_YET_RECRUITING; sponsor Eli Lilly and Company; intervention "eloralintide and tirzepatide" (DRUG)).
Not gradedEloralintide is being studied in a registered trial: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes (NCT07881432; PHASE3; NOT_YET_RECRUITING; sponsor Eli Lilly and Company; intervention "eloralintide and tirzepatide" (DRUG)).

Educational reference only — not medical advice.

What people report (anecdote)

Adverse events:

None recorded in our sources.

Effects measured:

Human trials: none found.

ANECDOTE

Loading…